Anti-SARS-CoV-2 Immunoglobulin Isotypes, and Neutralization Activity Against Viral Variants, According to BNT162b2-Vaccination and Infection History.
Front Immunol
; 12: 793191, 2021.
Article
Dans Anglais
| MEDLINE | ID: covidwho-1608200
ABSTRACT
Purpose:
To compare SARS-CoV-2 antigen-specific antibody production and plasma neutralizing capacity against B.1 wild-type-like strain, and Gamma/P.1 and Delta/B.1.617.2 variants-of-concern, in subjects with different Covid-19 disease and vaccination histories.Methods:
Adult subjects were 1) Unvaccinated/hospitalized for Covid-19; 2) Covid-19-recovered followed by one BNT162b2 vaccine dose; and 3) Covid-19-naïve/2-dose BNT162b2 vaccinated. Multiplex Luminex® immunoassays measured IgG, IgA, and IgM plasma levels against SARS-CoV-2 receptor-binding domain (RBD), spike-1 (S), and nucleocapsid proteins. Neutralizing activity was determined in Vero E6 cytopathic assays.Results:
Maximum anti-RBD IgG levels were similar in Covid-19recovered individuals 8â10 days after single-dose vaccination and in Covid-19-naïve subjects 7 days after 2nd vaccine dosing; both groups had ≈2fold higher anti-RBD IgG levels than Unvaccinated/Covid-19 subjects tracked through 2 weeks post-symptom onset. Anti-S IgG expression patterns were similar to RBD within each group, but with lower signal strengths. Viral antigen-specific IgA and IgM levels were more variable than IgG patterns. Anti-nucleocapsid immunoglobulins were not detected in Covid-19-naïve subjects. Neutralizing activity against the B.1 strain, and Gamma/P.1 and Delta/B.1.617.2 variants, was highest in Covid19-recovered/single-dose vaccinated subjects; although neutralization against the Delta variant in this group was only 26% compared to B.1 neutralization, absolute anti-Delta titers suggested maintained protection. Neutralizing titers against the Gamma and Delta variants were 33â77% and 26â67%, respectively, versus neutralization against the B.1 strain (100%) in the three groups.Conclusion:
These findings support SARS-CoV-2 mRNA vaccine usefulness regardless of Covid-19 history, and confirm remarkable protection provided by a single vaccine dose in people who have recovered from Covid-19.Mots clés
Texte intégral:
Disponible
Collection:
Bases de données internationales
Base de données:
MEDLINE
Sujet Principal:
Isotypes des immunoglobulines
/
Anticorps neutralisants
/
SARS-CoV-2
/
COVID-19
/
Vaccin BNT162
/
Anticorps antiviraux
Type d'étude:
Études expérimentales
/
Étude pronostique
/
Essai contrôlé randomisé
Les sujets:
Vaccins
/
Variantes
Limites du sujet:
Adulte
/
Adulte très âgé
/
Animaux
/
Femelle
/
Humains
/
Mâle
/
Adulte d'âge moyen
langue:
Anglais
Revue:
Front Immunol
Année:
2021
Type de document:
Article
Pays d'affiliation:
Fimmu.2021.793191
Documents relatifs à ce sujet
MEDLINE
...
LILACS
LIS